Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Phase 1 Recruiting
40 enrolled
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 Recruiting
134 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Phase 1 Recruiting
25 enrolled
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Phase 1 Recruiting
800 enrolled
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 Recruiting
188 enrolled
Talazoparib
Phase 1 Recruiting
24 enrolled
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Phase 1 Recruiting
307 enrolled
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Phase 1 Recruiting
60 enrolled
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Phase 1 Recruiting
97 enrolled
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Phase 1 Recruiting
250 enrolled
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Phase 1 Recruiting
226 enrolled
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Phase 1 Recruiting
19 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
Phase 1 Recruiting
100 enrolled
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 Recruiting
24 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Phase 1 Recruiting
100 enrolled
GUARDIAN-101
Phase 1 Recruiting
90 enrolled
VISTA
Phase 1 Recruiting
45 enrolled
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Phase 1 Recruiting
150 enrolled
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Phase 1 Recruiting
574 enrolled
A Study of PHN-012 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
165 enrolled
Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer
Phase 1 Recruiting
250 enrolled
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Phase 1 Recruiting
470 enrolled
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Phase 1 Recruiting
495 enrolled
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Phase 1 Recruiting
93 enrolled
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Phase 1 Recruiting
22 enrolled
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Phase 1 Recruiting
18 enrolled
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
Phase 1 Recruiting
190 enrolled
KUNLUN-001
Phase 1 Recruiting
18 enrolled
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Phase 1 Recruiting
24 enrolled
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Phase 1 Recruiting
180 enrolled
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Phase 1 Recruiting
90 enrolled
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
Phase 1 Recruiting
15 enrolled
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 1 Recruiting
604 enrolled
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
Phase 1 Recruiting
21 enrolled
POTENT
Phase 1 Recruiting
19 enrolled
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Phase 1 Recruiting
5 enrolled
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Phase 1 Recruiting
30 enrolled
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Phase 1 Recruiting
45 enrolled
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
Phase 1 Recruiting
20 enrolled
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1 Recruiting
15 enrolled
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Phase 1 Recruiting
28 enrolled
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Phase 1 Recruiting
12 enrolled
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
Phase 1 Recruiting
12 enrolled
Brodalumab in the Treatment of Immune-Related Adverse Events
Phase 1 Recruiting
11 enrolled
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Phase 1 Recruiting
69 enrolled
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
Phase 1 Recruiting
100 enrolled